Lifemin (Lisdexamfetamine Dimesylate)

Lisdexamfetamine dimesylate is a prodrug that is enzymatically converted to dextroamphetamine after oral ingestion. The active dextroamphetamine increases the release of norepinephrine and dopamine while inhibiting their reuptake, thereby enhancing neurotransmission in brain pathways that regulate attention and behavior.

The appropriate dose of Lifemin is individualized and determined by a qualified prescriber based on the patient’s age, clinical response, and tolerability. Dosage adjustments are made during follow‑up visits to achieve optimal therapeutic effect while minimizing side effects.

Safety data for lisdexamfetamine use in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician in consultation with the patient.

To order Lifemin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lifemin is a prodrug of dextroamphetamine, offering a smoother onset and longer duration compared with immediate‑release amphetamine salts. Unlike methylphenidate formulations, it provides a single daily dose and may have a lower potential for abuse due to its conversion step, though clinical choice depends on individual response and tolerability.

Lifemin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Lifemin is taken orally, usually once daily in the morning, with or without food. The tablet should be swallowed whole with a glass of water and not chewed, crushed, or divided, to ensure proper conversion to the active metabolite.

Serious risks include cardiovascular events such as hypertension or tachycardia, psychiatric effects like psychosis or severe mood swings, and the potential for dependence or abuse. Patients should be monitored regularly for these adverse outcomes, especially during treatment initiation or dose changes.

Lifemin is contraindicated in individuals with known hypersensitivity to lisdexamfetamine or any amphetamine, those who have taken monoamine oxidase inhibitors within the past 14 days, patients with severe cardiovascular disease, uncontrolled hypertension, or a history of psychosis.